# Nivolumab Plus Metformin in Metastatic Renal Cell Carcinoma

> **NCT06884683** · PHASE2 · TERMINATED · sponsor: **Fondazione Policlinico Universitario Agostino Gemelli IRCCS** · enrollment: 12 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT06884683
- **Lead sponsor:** Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-17
- **Primary completion:** 2023-09-13
- **Final completion:** 2023-09-13
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** slow enrollment
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06884683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06884683, "Nivolumab Plus Metformin in Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06884683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*